Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

A compound of the Formula I(a):

• wherein:
• R1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH═CH—R3 or CH═N—R3, where R3 is a substituted or unsubstituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• and
• R1 is a substituted or unsubstituted aryl or Y—Ar, where Y is O, S, C═CH2 C═O, S═O, SO2, CH2, CHCH3, NH, or N—(C1-C8 alkyl), and Ar is a substituted or unsubstituted aryl;
• or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

A compound of the Formula II:

• wherein:
• R1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH═CH—R3 or CH═N—R3, where R3 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• R4 and R7 are each independently hydrogen, OH, halo, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkenyl, aryloxy, thioaryl, CH2—OH, CH2—O—(C1-C8 alkyl), CH2—O-aryl, CH2—S—(C1-C8 alkyl), or CH2—S-aryl;
• and
• R5 and R6 are each independently hydrogen, OH, halo, Z-alkyl, Z-aryl, or Z—CH2CH═CH2, where Z is O, S, NH, or CH2 and the alkyl and aryl moiety of Z-alkyl and Z-aryl are each optionally substituted;
• or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

A compound of the Formula IV:

• wherein:
• R1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH═CH—R3 or CH═N—R3, where R3 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• Y is O, S, C═CH2, C═O, S═O, SO2, CH2, CHCH3, NH, or N—(C1-C8 alkyl);
• R9 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxyl, aryloxyl, cycloalkoxyl, NH—(C1-C8 alkyl), NH—(aryl), NH—(heteroaryl), N═CH—alkyl), NH(C═O)R11, or NH2, where R11 is independently selected from hydrogen, substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
• and
• R10 is independently selected from hydrogen, halogen, and lower-alkyl;
• or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.